AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.

Pfizer Inc.’s experimental treatment for an inflammatory bowel disease, acquired during 2021 as part of the company’s $6.7 billion Arena Pharmaceuticals deal, succeeded in a second late-stage study.

Pfizer announced positive top-line results from the company’s year-long Phase III trial of etrasimod for the treatment of ulcerative colitis (UC). Pfizer plans to pursue regulatory filings for the drug during 2022.

New global data analysis from Phesi shows the extent of the impact from the war in Ukraine on clinical development.

The U.S. health agency extended the review period for the expanded use of AbbVie Inc.’s psoriasis drug Skyrizi by three months, citing the need for more time to review additional data submitted by the company.

The U.S. Food and Drug Administration was reviewing the application for the use of Skyrizi in patients aged 16 years of age or older with moderate to severe Crohn’s disease, a type of inflammatory bowel disease.

AbbVie reported the company’s fourth-quarter 2021 and full-year financial results on Feb. 2, with worldwide net reviews up 7.4% to $14.89 billion for the quarter. Total revenues for 2021 were $56 billion. The company’s anchor product remains Humira, which will begin to lose exclusivity in 2023.

Theravance announced that the diversified biopharmaceutical company’s oral drug candidate for the possible treatment of ulcerative colitis failed to meet the primary endpoint of a Phase IIb study.

AbbVie’s Rinvoq continues to demonstrate the medicine’s clinical potential to become the heir-apparent to the company’s blockbuster drug Humira, which will lose patent protection in 2023. In the company’s second-quarter 2021 report, AbbVie touted advances Rinvoq made throughout the three months, including positive Phase III data in ulcerative colitis.

Galapagos announced new post-hoc analyses for the Belgium-based company’s Phase III SELECTION program for the JAK1 inhibitor filgotinib for ulcerative colitis, touting rapid symptom improvement and sustained steroid-free remission. 

Recent personnel movement throughout the healthcare industry includes a new CEO for both U.K.-based Orbit Discovery and Netherlands-based Azafaros.